Maple syrup urine disease (MSUD) or branched-chain ␣ -ketoaciduria is an autosomally inherited disorder in the catabolism of branched-chain amino acids leucine, isoleucine, and valine. The disease is characterized by severe ketoacidosis, mental retardation, and neurological impairments. MSUD can be classified into genetic subtypes according to the genes of the branched-chain ␣ -ketoacid dehydrogenase (BCKD) complex which are affected in patients. We describe here four intronic deletions and an intronic nucleotide substitution in the E2 transacylase gene of type II MSUD, in which the E2 subunit of the BCKD complex is deficient. These new E2 mutations comprise an internal 3.2-kb deletion in intron 4 (causing a 17-bp insertion in mRNA), an internal 12-bp (ttaccttgttac) deletion in intron 4 (creating a 10-bp insertion), a 10-bp (catttctaG) deletion in intron 10/ exon 11 junction (leading to a 21-bp deletion), a 2-bp deletion in the exon 5/intron 5 junction (ATgt → A-t) (resulting in the skipping of exon 5), and a G to A transition at nucleotide Ϫ 7 of intron 9 (causing a 6-bp insertion). These intronic mutations were initially detected by secondary alterations in the mutant E2 mRNA, as a result of aberrant splicing. The 3.2-kb deletion in intron 4 was determined by the amplification of the entire intron from both a normal subject (11.2 kb) and a homozygous patient (8 kb) by long PCR, followed by subcloning and sequencing of regions flanking the deletion. Similar methods were used to identify and characterize the other intronic alterations. Our results depict heretofore undescribed splicing errors caused by the deletion of internal intronic segments, and provide an approach for detecting this class of novel and rare human mutation. The association of the thiamine-responsive phenotype with a subset of the type II MSUD patients studied is also discussed. 
Introduction
Maple syrup urine disease (MSUD) 1 or branched-chain ␣ -ketoaciduria is an autosomal recessively inherited deficiency in the mitochondrial branched-chain ␣ -ketoacid dehydrogenase (BCKD) complex. The biochemical basis of this disease is the inability to metabolize branched-chain ␣ -ketoacids (BCKA) derived from the essential branched-chained amino acids (BCAA) leucine, isoleucine, and valine. The elevated BCAAs and BCKAs may have severe clinical consequences including ketoacidosis, mental retardation, and neurological impairment. Variations in clinical presentations have led to the classification of MSUD into five clinical phenotypes, i.e., classic, intermediate, intermittent, thiamine-responsive, and E3-deficient forms (1, 2) . The classic form, which accounts for 75% of MSUD patients, is manifested within the first 2 wk of life by poor feeding, lethargy, seizures, coma, and death if left untreated. Intermediate MSUD is associated with elevated BCAAs and BCKAs, with progressive mental retardation, and developmental delay without a history of catastrophic illness. An intermittent form of MSUD has normal levels of BCAAs, normal intelligence and development until a stress, e.g., infection, precipitates decompensation with ketoacidosis without seriously affecting intelligence and development. Thiamineresponsive MSUD is similar to the intermediate or intermittent phenotype, but responds to pharmacologic doses of thiamine with normalization of the level of BCAAs (2) . The E3-deficient MSUD is caused by defects in the dihydrolipoyl dehydrogenase (E3) component of the BCKD complex that is common to the pyruvate and ␣ -ketoglutarate dehydrogenase complexes. Patients with E3 deficiency have dysfunction of all three enzyme complexes and usually die in infancy with severe lactic acidosis (3) .
The mammalian BCKD complex is a mitochondrial multienzyme complex, which catalyzes the oxidative decarboxylation of the three BCKA derived from BCAA (4, 5) . The enzyme complex is organized around a cubic core comprising 24 identical dihydrolipoyl transacylase (E2) subunits, to which branched-chain ␣ -keto acid decarboxylase (E1), E3, a specific kinase, and a specific phosphatase are attached through ionic interactions. The kinase and the phosphatase are responsible for the regulation of BCKD complex by a reversible phosphorylation (inactivation)/dephosphorylation (activation) mecha-nism (6) . The E1 component is a heterotetramer consisting of two E1 ␣ and two E1 ␤ subunits. The E3 component, a flavoprotein, is a homodimer. Therefore, there are in total six genetic loci that contribute to the BCKD complex, and mutations in all four different catalytic subunits (E1 ␣ , E1 ␤ , E2, and E3) have been described in MSUD patients. Genetic subtypes of MSUD have been proposed on the basis of the subunit affected (1) . These include type IA MSUD affecting the E1 ␣ subunit; type IB affecting the E1 ␤ subunit; type II, affecting the E2 subunit; and type III, affecting the E3 subunit. Types IV and V are reserved for MSUD involving the kinase and the phosphatase, respectively, and have not been reported.
The E2 gene perturbed in type II MSUD is located on chromosome 1p31 (7). The gene contains 11 exons and spans 68 kb (8) . The E2 gene product comprises three independently folded domains, i.e., lipoyl-bearing, E1/E3-binding, and innercore domains which are connected by flexible hinge regions. This domain structure is highly conserved between different E2 proteins of the ␣ -ketoacid dehydrogenase complexes. Several mutations in the E2 gene of type II MSUD patients have been described, including a 17-bp insertion 5 Ј to exon 5, a T to G transversion corresponding to an F215C substitution in exon 7 from a thiamine-responsive patient, WG-34 (9), and a 2-bp deletion in exon 2 and a G to T transversion (E163X) in exon 6 (10) . A G to A transition at the last nucleotide of exon 8 (11) and a 1-bp deletion at the 5 Ј donor site of intron 8 (12) were also described, resulting in the skipping of exon 8.
To further elucidate relationships between the genotype and biochemical mechanisms underlying MSUD, we have undertaken an investigation to identify additional mutations in type II MSUD. In this communication, we report five new mutations in the E2 gene which cause type II MSUD. It is noteworthy that a significant number of these mutations involve rare deletions of internal intronic segments which lead to secondary insertions/deletions in the transcript through utilization of cryptic or new splice sites. The occurrence of these insertion/deletion mutations was initially found by reverse transcription (RT)-PCR and direct sequencing of the mutant E2 mRNA. A 3.2-kb internal deletion in intron 4 was established by amplification and analysis of the entire intron (normal size: 11.2 kb). Moreover, there is an apparent correlation of type II MSUD mutations with the thiamine-responsive phenotype. The significance of this correlation in the treatment of type II patients is discussed.
Methods
Cell cultures and cell lines. Lymphoblast and fibroblast cell cultures were grown as described previously (13) . Fibroblasts or lymphoblasts prepared from blood specimens by infection with EBV (14) were used for analysis. The following is a list of physicians who provided patients' blood samples or fibroblasts for studies: C.E. 
The exon number is assigned according to the structure of the human E2 gene (8) . Nucleotide positions in the coding region are based on the complete human E2 cDNA sequence (27) . ϩ refers to the 5Ј→3Ј orientation and Ϫ the 3Ј→5Ј orientation. bec); and MGF-497 (fibroblasts), Dr. Vivian Shih (Massachusetts General Hospital, Boston, MA).
Reverse transcription and amplification of E2 mRNA and sequencing. For RT-PCR, the first strand cDNA was reverse-transcribed from 10 g of total RNA from fibroblasts or lymphoblasts derived from patients or normal subjects using primer hE2-3Ј (Table I) and the AMV reverse transcriptase (Promega, Madison, WI). The entire E2 cDNA was amplified using the 5Ј and 3Ј primers (Table I) flanking the coding region. Direct sequencing of amplified cDNA was carried out using the Promega fmol ™ DNA sequencing system according to the supplier's instructions. For compound-heterozygous mutations, the amplification product was subcloned and doublestranded sequencing was performed (15) .
Genomic amplification of E2 exons and sequencing. For genomic amplification, the entire coding region of each exon and intron/exon boundary was amplified from genomic DNA prepared from normal or patient's cells using Taq DNA polymerase from Promega. The sense and antisense primers used for amplification of the 11 E2 exons are shown in Table I . Direct sequencing of amplified products, subcloning, and double-stranded sequencing were as described above.
Amplification of intron 4. The entire intron 4 (11.2 kb in length) of the human E2 gene was amplified from genomic DNA of lymphoblasts using the Expand ™ long template PCR system from Boehringer-Mannheim (Mannheim, Germany). The sense and antisense primers are located in exon 4 and exon 5, respectively, with the following sequences: 5Ј-GCTTCTGTTACCATCACTAGTCGTTAT-GATGG-3Ј (sense) (bases 330-365) and 5Ј-CTCTTGGTGTGTAT-GTTCATCATGAGACACTGCAG-3Ј (antisense) (bases 509-475). The amplification mixture contained 50 mM Tris-HCl, pH 9.2, 350 m of the dNTP mixture, 300 nM each of the sense and antisense primers, 16 mM (NH 4 ) 2 SO 4 , 1.75 mM MgCl 2 , 0.75 l of the Expand ™ enzyme mixture, and 500 ng-1 g of genomic DNA in a final volume of 50 l. Amplification was carried out in a thin-walled reaction tube on a programmable thermal controller (model PTC-100; MJ Research Inc., Watertown, MA) with denaturation of the template at 93ЊC for 2 min. This was followed by 10 cycles of denaturation at 93ЊC for 30 s, and annealing and elongation at 68ЊC for 10 min. 20 more cycles were performed with denaturation at 93ЊC for 30 s, annealing at 68ЊC for 30 s, and elongation at 68ЊC for 10 min, with a 20-s increment for elongation in each cycle.
Other procedures. Western blotting was performed as described previously (16) . Activity of the BCKD complex in fibroblasts or lymphoblasts was determined by measuring CO 2 release when intact cells were incubated in ␣-keto[1- (10, 13) . The heteroduplex analysis for mutations was carried out as described previously (17) .
Results

Identification of the type II MSUD cells.
Lymphoblasts or fibroblasts derived from suspected MSUD patients were assayed for the rate of decarboxylation of ␣-keto[1-
14
C]isovalerate by the intact cell assay. MSUD was confirmed by either markedly reduced or no decarboxylation of the ␣-ketoacid when the results with patients' cells were compared to those with normal. To localize the subunit of the BCKD complex affected, cell lysates from established MSUD patients were subjected to Western blotting using antibody to E1␣, E1␤, or E2 subunits as a probe. The type II MSUD cells used in this study showed either the absence or markedly lower than normal levels of E2 protein (data not shown).
Exonic insertions/deletions caused by internal deletions of intronic segments. We recently studied a type II MSUD patient (S.G.), in which we were unable to amplify exon 5 of the E2 gene using a pair of primers (5F and 5R, Table I ) flanking exon 5. RT-PCR of the total RNA prepared from lympho- .2 kb) and the mutant (8.0 kb) were amplified by long PCR, and the amplified DNA digested with EcoRI. Southern blot analysis showed that a 300-bp EcoRI fragment from the mutant PCR product hybridized strongly with an oligonucleotide probe corresponding to the 17-bp insert in the mutant E2 mRNA. This DNA fragment was isolated, subcloned, and sequenced. Nucleotide sequences flanking the 3.2-kb deleted region (del 3.2kb) are shown. The upper and lower arrows depict the original and new 3Ј-splice sites, respectively. Normal sequences in this region are shown in Fig. 2 A  (lanes 2 and 3) . The two MSUD patients (N.R. and L.J.) are not affected in this region of the E2 gene. (C) Proposed mechanism for the 17-bp insertion in the mutant E2 mRNA. The 3.2-kb deletion occurs immediately 5Ј to the 14-bp intronic sequence present in the E2 transcript. The aaa trinucleotides that are also present in the 17-bp insert are located between the 3.2-kb deletion and the invariant ag dinucleotides that are used as a cryptic 3Ј acceptor splice site. The lowercase letters represent intronic sequences. The uppercase letters refer to exonic or mRNA sequences. The 17-bp inserted intronic sequence in the mRNA is underlined. The original (base Ϫ29) and the new branch point based on a consensus sequence YTRAY (25) are indicated by asterisks.
blasts and direct sequencing revealed that S.G. is homozygous for the 17-bp insertion (5Ј AAATACCTTGTTACCAG 3Ј) which was shown previously to occur in compound-heterozygote thiamine-responsive patient WG-34 (2, 9). Intron 4 of the E2 gene was subsequently amplified using genomic DNA from normal and from S.G. cells as templates and using a sense and an antisense primer located in exon 4 and exon 5, respectively (see Methods). The approximate sizes of PCR products were estimated by adding the sizes of EcoRI-digested fragments of the amplified DNA (data not shown). An 11.2-kb PCR product corresponding to intron 4 was obtained with genomic DNA from normal cells as template (Fig. 1 A, lane 3) . In contrast, an 8-kb fragment corresponding to intron 4 was generated with genomic DNA from the homozygous patient S.G. The lower intensity of the 11.2-kb band in S.B. is probably due to a preferential amplification of the shorter 8-kb fragment during long PCR. The intronic sequences flanking the deleted 3.2-kb region have been determined (Fig. 1 B) . Based on these sequences, a mechanism for the 17-bp insertion in mutant E2 mRNA is shown in Fig. 1 C. According to this mechanism, a new 3Ј acceptor site (arrow) upstream of the intact original site is used, which causes insertion (underlined) of the 14-bp intronic sequence and the determined aaa intronic triplet in the mutant E2 mRNA from S.G. (Fig. 1 C) . Since no normal E2 mRNA was detected by direct sequencing of amplified cDNAs, the original 3Ј-splice site is not used in the aberrant splicing.
Type II MSUD mutations in the compound-heterozygous patient S.B. were initially studied by amplifying the 11 exons of the E2 gene from this subject. Heteroduplex analysis of amplified E2 exons indicated possible mutations in exon 5. Amplification and direct sequencing of the exon 5 region showed an apparent homozygous 12-bp (ttaccttgttac) deletion in the 3Ј-terminal region of intron 4 (Fig. 2 A) . However, RT-PCR of the E2 mRNA followed by direct sequencing showed a heterogeneous sequence pattern after exon 4. Subcloning of the RT-PCR products and subsequent sequencing showed the presence of only two types of mutant E2 mRNA. One contained the above 17-bp insertion 5Ј to exon 5, indicating the presence of the IVS4del[Ϫ3.2 kb:Ϫ15] allele. The second mutant transcript harbored a novel 10-bp insertion (TTAAGT-TCAGA), also 5Ј to exon 5. The results explained the apparent homozygosity of S.B. observed in exon amplification. The exon 5 region of the IVS4del[Ϫ3.2 kb:Ϫ15] allele in S.B. could not be amplified, since the sense primer used was located in the deleted 3.2-kb intronic segment. The 12-bp intronic deletion ( Fig. 2 B, boxed) causes the sole utilization of a new 3Ј-splice site (arrow), resulting in the insertion of 10 bp of the downstream 3Ј-intronic sequence (underlined). This allele is named IVS4del[Ϫ15:Ϫ4].
Based on the absence of the E2 subunit on Western blotting, it was determined that patient W.J. had type II MSUD. RT-PCR was carried out on total RNA of lymphoblasts prepared from this patient. Direct sequencing of the PCR product showed a homozygous 21-bp deletion (GCCATTC-CCCGATTTAACCAG), proximal to the 5Ј-terminus of exon 11. No normal E2 mRNA was present. Genomic DNA from W.J. was amplified using a sense primer located upstream (11F , Table I ) of the intron 10/exon 11 splice junction and an antisense primer in the noncoding region of exon 11 (hE2-3Ј). showing the 12-bp deletion. Exon 5 region was amplified from genomic DNA of three type II MSUD patients using primers 5F and 5R (Table  I) . Sequencing samples were applied in groups according to the nucleotides A, C, G, and T. Lane 1, patient S.B.; lane 2, patient N.R.; lane 3, patient L.J. Boxed sequences are the deleted sequence of 12 bp from intron 4. S.B. is a heterozygote for the 12-bp intronic deletion. The other allele contains the 3.2-kb deletion in intron 4 ( Fig. 1) , and was not amplified because the sense primer was in the deleted region. The other two MSUD patients are normal in this region. (B) Utilization of a new 3Ј acceptor splice site (arrow) upstream of the normal in intron 4 results in a 10-bp insertion (underlined) in the mutant E2 mRNA. The lowercase letters refer to the intronic sequences, and uppercase letters are exonic or mRNA sequences.
Direct sequencing of the amplified genomic DNA indicated that the 9 bp at the 3Ј-end of intron 10 including the invariant 3Ј ag splice site and one terminal G nucleotide of exon 11 (catttctagG) were deleted (Fig. 3 A) . This deletion completely abolishes the normal 3Ј-splice site of intron 10, which leads to the activation of a cryptic 3Ј-splice site (the original site is destroyed) located in exon 11 ( Fig. 3 B, arrow) . This aberrant splicing results in the elimination of 21 bp (Fig. 3 B, boxed) from the 5Ј-end of exon 11 in the E2 mRNA of this patient. The allele is designated IVS10del[Ϫ9:ϩ1].
A thiamine-responsive type II MSUD patient, C.E., was previously shown to be a compound-heterozygote for a 2-bp deletion allele (90delAT) in exon 2 of the E2 locus (10) . RT-PCR of the E2 mRNA was carried out with lymphoblastoid cells from this patient. Sequencing of subcloned PCR product disclosed that exon 5 was frequently skipped (10) . A pair of primers flanking exon 5 were therefore used to amplify this region with genomic DNA from C.E. as template. Sequencing of the subcloned PCR products revealed a deletion of 2 bp at the exon 5/intron 5 junction (ATgt→A-t) of one allele (Fig. 4 A) . The allele is designated IVS5del[Ϫ1:ϩ1]. The deletion of the invariant 5Ј-splice site results in the skipping of exon 5 (Fig. 4 B) .
A classic MSUD patient, A.E., was the progeny of consanguineous Moroccan parents. He and an older brother both had episodes of lactic acidosis and died of progressive neurological symptoms. RT-PCR of A.E.'s E2 mRNA and direct sequencing revealed that the patient was homozygous for a 6-bp insertion derived from the 3Ј-terminal sequence of intron 9. The normal E2 mRNA was not detected. Subsequently, the sequence of intron 9 upstream of the 3Ј-splice site was amplified and directly sequenced. The results showed an A to G transition at nucleotide Ϫ7 of intron 9 (Fig. 5 A) . This causes the creation of a new 3Ј-splice site, resulting in an invariant retention of the 6-bp intronic sequence (Fig. 5 B) . The inserted bases harbor a stop codon TAG immediately 5Ј to exon 10, which causes the absence of the E2 subunit.
Discussion
This report describes five intronic mutations in type II MSUD which produce secondary insertion/deletion or exon skipping in the mutant E2 transcripts. Some of these alterations in the E2 mRNA are the result of splicing errors by a novel mechanism. The majority of the splicing errors reported to date are associated with mutations in the 5Ј and 3Ј-splice sites. Of the 5Ј-splice site mutations, 60% involve the invariant gt dinucleotide. Among the 3Ј-splice site mutations, 87% perturb the invariant ag nucleotide pair (18, 19) . However, aberrant splicing caused by deletion of internal intronic segments, as shown in this study, has not been described. The absence of this mechanism in the literature is probably due to inherent difficulties in detecting internal intronic deletions especially with large introns (see below). It is noteworthy that 5 (this study) out of the 19 currently known E2 mutations involve deletions or base substitutions in the introns (20) . The basis for this relatively high frequency of intronic alteration in type II MSUD is mostly unknown. In the case of the IVS10del[Ϫ9:ϩ1] allele, however, the 10-bp deletion is associated with a pair of tandem direct repeats, which occur either within (intronic catt) or 3Ј to (exonic CATT) the deleted bases (Fig. 3 B, underlined) . The data strongly suggest slipped mispairing during DNA replication as a mechanism for the gene deletion, as proposed by Krawczak and Cooper (21) . In contrast, the 15 known mutations in the E1␣ gene in type IA MSUD occur only in the exons (20) .
The intronic mutations described in this study were first suggested by amplification of the mutant E2 mRNA, followed by sequencing of cDNA subclones (9) or direct sequencing of the RT-PCR product. For example, the IVS4del[Ϫ3.2 kb:Ϫ15] allele produces a 17-bp insertion in the E2 mRNA immediately 5Ј to exon 5. The insertion was initially detected in a cDNA subclone from type II MSUD patient WG-34, who was a compound heterozygote for this allele (9) . However, the au- thenticity of the 17-bp insertion allele was questioned because of the failure to show intronic alterations, when intron 4 of WG-34 was amplified with the primer pair 5F and 5R (Table  I) . We were later unable to amplify exon 5 from a type II MSUD patient, S.G., who was homozygous for the 17-bp insertion at the mRNA level. The question then became whether this patient had an intronic deletion which encompassed the sense primer (5F) region. This prompted the amplification of the entire intron 4 from a normal subject (11.2 kb) and S.G. by long PCR. Subcloning and sequencing of restriction fragments of the PCR products identified a 3.2-kb internal segment of intron 4 which was truncated in the homozygous IVS4del[Ϫ3.2 kb:Ϫ15] allele of S.G. Thus, our studies demonstrate the use of long PCR in analyzing internal intronic mutations and emphasize the importance of RT-PCR of mutant mRNA as a first step in detecting secondary insertions/deletions caused by internal intronic alterations. However, there are limitations in the approach of RT-PCR of mRNA. For example, certain exonic alterations generate nonsense mutations in early coding regions, rendering the mRNA unstable (22) . In this case, amplification and direct sequencing of exons from genomic DNA is necessary to detect the exonic mutations (22) .
A common feature of the intronic mutations described in this study involves aberrant splicing through the activation of cryptic splice sites (when the original site has been destroyed) or the creation or utilization of new splice sites (when the original site remains intact) in the E2 gene. and extends the theory of exon definition as a guide for the splice site selection. The concept of exon definition dictates that in the pre-mRNA with large introns, the splicing machinery searches for a pair of closely spaced splice sites in an exonic polarity (23) . This mechanism imposes a size constraint for internal exons, which can be no larger than 400 nucleotides. The new 3Ј-splice site was not functional in the normal E2 gene because it was far upstream of the 3Ј-end of exon 5. The new site was activated only after it was moved closer to exon 5 by the internal deletion of intron 4 in the IVS4del[Ϫ3.2 kb:Ϫ15] allele. The strength of this new 3Ј-splice site is similar to the original site, as indicated by the consensus scores (24) of 73.5 and 84.6%, respectively (Table II) . The fact that the new 3Ј-splice site is solely used in the mutant allele provides evidence for 5Ј→3Ј polarity in exon definition. That is, between the two proximal splice sites of similar strength, the upstream splice site is first encountered by the spliceosome in exon scanning, and is exclusively used for RNA splicing. It should also be mentioned that a putative normal branch point (nucleotide Ϫ29) based on a consensus sequence YTRAY (25) is deleted in the IVS4del[Ϫ3.2 kb:Ϫ15] allele (Fig. 1 C) . An alternate branch point 13 bp upstream of the new 3Ј-splice site renders this site suitable for 3Ј splicing.
As for the IVS4del[Ϫ15:Ϫ4] allele, the 12-bp intronic deletion near the original 3Ј-splice site in intron 4 reduces the strength of the original site with the consensus score decreasing from 84.6 to 66.4% (Table II) . This results in the sole usage of a new upstream 3Ј-splice site which has a relatively strong consensus score of 79.5% (Table II) . It is noted, however, that the new and original 3Ј-splice sites are of similar strength and in close vicinity to each other (20 bp apart). Despite being upstream of the original site, the new site is not used in normal splicing. The reason is not clear, but may suggest additional intronic sequence specificities in influencing the 3Ј-splice site selection.
In the IVS9-7A→G allele, an A to G transition created a new 3Ј-splice site, which is used entirely over the downstream authentic 3Ј-splice site. This causes a retention of 6 bp of intron 9 sequence juxtaposed to the 5Ј-terminus of exon 10. The consensus score shows 85% for the new 3Ј-splice site and 70.8% for the original site (24) . The data again support the concept of exon scanning in 5Ј→3Ј polarity, and the occurrence of a stronger 3Ј-splice site through the A to G mutation results in an exclusive recognition of the newly created site by the spliceosome. An A to G transition was also reported in intron 16 of the muscle phosphofructokinase gene in a patient with glycogenosis type VII (Tarui disease) (26) . This intronic mutation leads to the retention of 63 nucleotides of intron 16 by a mechanism similar to that which occurs in the IVS9-7 A→G allele of this study. As for the IVS10del[Ϫ9:ϩ1] allele, a *The new 3Ј-splice site refers to the alternate site which is used when the original 3Ј-splice site is still intact. The cryptic 3Ј-splice site denotes the alternate site which is activated after the original site is destroyed as a result of the mutation (19) . ‡ The consensus score was calculated by assigning a score to each of the 14 nucleotides flanking the invariant ag dinucleotide in the allele, according to compatibility of the base to the consensus sequence (25) . A 100% consensus score indicates complete compatibility and the maximal strength of the splice site. ‡ The F215C missense mutation in exon 7 was previously reported (9) . § MGF-497 was previously documented as a thiamine-responsive/intermittent patient under the code name P.G. (30) .
ʈ The R230G missense mutation will be described elsewhere. ¶ Not determined.
deletion of a 3Ј-terminal region including the authentic 3Ј-splice site (consensus score 91.5%) led to the activation of a cryptic site (consensus score 75.5%) downstream which causes a 21-bp truncation of the exon. Table III summarizes the occurrence of the E2 mutations in the seven MSUD patients studied. The F215C missense mutation was described previously (9) , and the R230G missense mutation will be reported elsewhere. 2 The remaining five alleles are those documented in this study. The IVS4del[Ϫ3.2 kb: Ϫ15] allele was originally detected in a compound-heterozygous type II MSUD patient, WG-34, who lived in Montreal, Canada (9) . This allele also occurred in a homozygous patient (S.G.) from the same city and in two compound heterozygotes, one in Minnesota (S.B.) and the other in Boston (MGF-497) (30) as described in this study. The relative geographical proximity among these patients suggests a Founder effect for the mutation. Moreover, these patients have either the intermittent/thiamine-responsive (WG-34 and MGF-497) or the classic (S.G. and S.B.) MSUD clinical phenotype, depending on the nature of mutation in the second allele. Of interest is that another classic type II MSUD patient (E.C.), who is compoundheterozygous for the IVS5del[Ϫ1:ϩ1] allele and the 90delAT allele, is also responsive to thiamine. We have recently found nine additional E2 alleles, including F215C in WG-34, which occur in several thiamine-responsive MSUD patients. 2 The data indicate a correlation between a subset of type II MSUD and the thiamine-responsive clinical phenotype. Type II MSUD patients carrying other mutant E2 alleles exhibit the classic (e.g., S.G., S.B., W.J., and A.E.) phenotype (Table III) . However, these patients have not been quantitatively studied for thiamine responsiveness. It is probable that additional type II patients with low or unmeasurable BCKD complex activity may still benefit from high doses of thiamine administration with improved tolerance of dietary branched-chain amino acids.
It should also be emphasized that no loci other than E2 of the BCKD complex are affected in documented thiamineresponsive patients that we (1, 9, 20) or others (28) have studied. The findings strongly suggest that a normal E1 component is a prerequisite for the thiamine-responsive phenotype. The presence of residual BCKD activity in the two type II MSUD patients (WG-34 and MGF-497) is associated with the expression of the mutant E2 protein as detected by Western blotting (Table III) . The residual enzyme activity may explain the milder intermittent phenotype in addition to the thiamine responsiveness in these patients. Our working hypothesis is that a normal E2 component, when complexed with E1, is essential for high affinity of the latter enzyme for thiamine pyrophosphate. This may explain the dependence of the responsive MSUD patients on high doses of thiamine (1, 9, 20) . Others have proposed that thiamine pyrophosphate stabilizes enzyme components of the BCKD complex, thereby improving the patient's tolerance for BCAAs (31) . The biochemical mechanism for thiamine response in type II patients is currently under investigation.
